- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06075953
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-evaluering av betingelser for aktiv overvåkingsegnethet som behandling
DCIS: RECAST-forsøk - Duktalt karsinom in situ: re-evaluering av betingelser for aktiv overvåkingsegnethet som behandling: en pilotstudie for forebygging av brystkreft
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease.
Participants will be asked to receive control hormonal therapy or an investigational hormonal therapy treatment. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation participants will have the option to continue on the treatment. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to provide blood sample to understand their immune status, provide saliva sample for genetic testing, provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with Ductal cell Carcinoma In Situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. The current management of most patients with DCIS involves surgical intervention with or without radiation, similar to more aggressive breast cancers. These treatments can come with some significant health effects.The main question this study aims to answer is: to determine whether novel endocrine therapy increases the fraction of patients who will be suitable for long-term active surveillance.
Participants will be asked to take one of three investigational study medication (z-Elacestrant, Testosterone + Anastrazole, or Endoxifen) or receive control hormonal therapy (Tamoxifen or an aromatase inhibitor), depending on the treatment to which they have been randomized. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation, participants will have the option to continue on the treatment, with follow up evaluations of Mammogram and MRI at 6 month intervals. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to:
- Provide blood sample to understand their immune status
- Provide saliva sample for genetic testing
- Provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.
Participants will be followed annually for 10 years.
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Tammy Neseth, MA, CCRP
- Telefonnummer: +1 (507) 269-8060
- E-post: t.neseth@qlhc.org
Studer Kontakt Backup
- Navn: Sabrina Mayhew, Ph.D. Nursing
- Telefonnummer: +1 (888) 282-7099
- E-post: s.mayhew@qlhc.org
Studiesteder
-
-
California
-
Berkeley, California, Forente stater, 94158
- Rekruttering
- Berkeley Outpatient Center
-
Ta kontakt med:
- Niloufar Abdollahi
- Telefonnummer: 415.476.3322
- E-post: Niloufar.abdollahi@ucsf.edu
-
Hovedetterforsker:
- Jordan Jackson, MD
-
Ta kontakt med:
- Dasha Peiris
- Telefonnummer: 415-533-0141
- E-post: Dasha.Peiris@ucsf.edu
-
Duarte, California, Forente stater, 91010
- Rekruttering
- City of Hope -Duarte Cancer Center
-
Hovedetterforsker:
- Jennifer Tseng, MD
-
Ta kontakt med:
- Mellissa Henry, RN, MSN, FNP-C
- Telefonnummer: 626-713-8895
- E-post: mehenry@coh.org
-
Irvine, California, Forente stater, 92618
- Rekruttering
- City of Hope - Lennar Foundation Cancer Center
-
Hovedetterforsker:
- Jennifer Tseng, MD
-
Ta kontakt med:
- Mellissa Henry, RN, MSN, FNP-C
- Telefonnummer: 626-713-8895
- E-post: mehenry@coh.org
-
Los Angeles, California, Forente stater, 90095
- Rekruttering
- UCLA
-
Ta kontakt med:
- Sophia Quiroz, Clinical Research Coordinator
- Telefonnummer: 310-794-0130
- E-post: SQuiroz@mednet.ucla.edu
-
Hovedetterforsker:
- Mediget Teshome, MD
-
San Francisco, California, Forente stater, 94158
- Rekruttering
- UCSF
-
Hovedetterforsker:
- Jordan Jackson, MD
-
Ta kontakt med:
- Dasha Peiris
- Telefonnummer: 415-533-0141
- E-post: Dasha.Peiris@ucsf.edu
-
South Pasadena, California, Forente stater, 91030
- Rekruttering
- City of Hope
-
Hovedetterforsker:
- Jennifer Tseng, MD
-
Ta kontakt med:
- Mellissa Henry, RN, MSN, FNP-C
- Telefonnummer: 626-713-8895
- E-post: mehenry@coh.org
-
Walnut Creek, California, Forente stater, 94598
- Rekruttering
- John Muir Health
-
Ta kontakt med:
- Jen Johnson, Clinical Research Coordinator
- Telefonnummer: 925-674-2580
- E-post: Jen.Johnson@johnmuirhealth.com
-
Hovedetterforsker:
- Monica Eigelberger, MD
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20010
- Rekruttering
- MedStar Washington Hospital Center
-
Hovedetterforsker:
- Marc Boisvert, MD
-
Ta kontakt med:
- Hiwot Guebre-Xabiher, Research Manager
- Telefonnummer: 202-877-8839
- E-post: Hiwot.Guebre-Xabiher@medstar.net
-
-
Florida
-
Tampa, Florida, Forente stater, 33612
- Rekruttering
- Moffitt Cancer Center
-
Ta kontakt med:
- Neveen Abdo, Clinical Research Coordinator
- Telefonnummer: 727-748-9345
- E-post: Neveen.abdo@moffitt.org
-
Hovedetterforsker:
- Laura Kruper, MD
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Winship Cancer Institute, Emory University
-
Hovedetterforsker:
- Clara Farley, MD
-
Ta kontakt med:
- Winship Clinical Trials Office
- Telefonnummer: 1-404-778-1868
- E-post: winshipcto@emory.edu
-
Ta kontakt med:
- Trisha Burrello
- E-post: trisha.n.burrello@emory.edu
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60637
- Rekruttering
- University of Chicago Medical Center
-
Ta kontakt med:
- Vhenyse Encarnacion
- E-post: vhenyse.encarnacion@bsd.uchicago.edu
-
Hovedetterforsker:
- Betty Fan, MD
-
-
Minnesota
-
Maple Grove, Minnesota, Forente stater, 55369
- Rekruttering
- Maple Grove Cancer Center
-
Ta kontakt med:
- Oncology Access Nurse
- Telefonnummer: 612-624-2620
- E-post: ccinfo@umn.edu
-
Hovedetterforsker:
- Jane Hui, MD
-
Minneapolis, Minnesota, Forente stater, 55455
- Rekruttering
- University of Minnesota
-
Ta kontakt med:
- Oncology Access Nurse
- Telefonnummer: 612-624-2620
- E-post: ccinfo@umn.edu
-
Hovedetterforsker:
- Jane Hui, MD
-
Minneapolis, Minnesota, Forente stater, 55404
- Rekruttering
- Hennepin Healthcare -Minneapolis
-
Ta kontakt med:
- Hannah Merrill
- Telefonnummer: 952-993-0996
- E-post: hannah.merrill@parknicollet.com
-
Ta kontakt med:
- Niki Hoese
- Telefonnummer: 952-993-1585
- E-post: nicole.hoese@parknicollet.com
-
Hovedetterforsker:
- Satya Bommakanti, MD
-
Saint Louis Park, Minnesota, Forente stater, 55426
- Rekruttering
- Health Partners - Frauenshuh Cancer Center
-
Ta kontakt med:
- Hannah Merrill
- Telefonnummer: 952-993-0996
- E-post: hannah.merrill@parknicollet.com
-
Ta kontakt med:
- Niki Hoese
- Telefonnummer: 952-993-1585
- E-post: nicole.hoese@parknicollet.com
-
Hovedetterforsker:
- Rachel Lerner, MD
-
Saint Paul, Minnesota, Forente stater, 55101
- Rekruttering
- Health Partners - Regions Hospital
-
Ta kontakt med:
- Hannah Merrill
- Telefonnummer: 952-993-0996
- E-post: hannah.merrill@parknicollet.com
-
Ta kontakt med:
- Niki Hoese
- Telefonnummer: 952-993-1585
- E-post: nicole.hoese@parknicollet.com
-
Hovedetterforsker:
- Rachel Lerner, MD
-
-
New Jersey
-
Englewood, New Jersey, Forente stater, 07631
- Rekruttering
- Englewood Hospital and Medical Center
-
Ta kontakt med:
- Kayla Williams
- Telefonnummer: 9786 201-894-3000
- E-post: kayla.williams@ehmchealth.org
-
Hovedetterforsker:
- Jennifer Marti, MD
-
-
New York
-
New York, New York, Forente stater, 10011
- Rekruttering
- Mount Sinai Chelsea
-
Hovedetterforsker:
- Tara Balija, MD
-
Ta kontakt med:
- Contact: Site Public Contact
- Telefonnummer: 212-824-7309
- E-post: CRSU@mssm.edu
-
New York, New York, Forente stater, 10029
- Rekruttering
- Icahn School of Medicine at Mount Sinai
-
Hovedetterforsker:
- Tara Balija, MD
-
Ta kontakt med:
- Contact: Site Public Contact
- Telefonnummer: 212-824-7309
- E-post: CRSU@mssm.edu
-
New York, New York, Forente stater, 10019
- Rekruttering
- Mount Sinai West
-
Hovedetterforsker:
- Tara Balija, MD
-
Ta kontakt med:
- Contact: Site Public Contact
- Telefonnummer: 212-824-7309
- E-post: CRSU@mssm.edu
-
New York, New York, Forente stater, 10003
- Rekruttering
- Mount Sinai Union Square
-
Hovedetterforsker:
- Tara Balija, MD
-
Ta kontakt med:
- Contact: Site Public Contact
- Telefonnummer: 212-824-7309
- E-post: CRSU@mssm.edu
-
The Bronx, New York, Forente stater, 10461
- Rekruttering
- Montefiore Medical Center (Hutchinson Campus Tower 1)
-
Ta kontakt med:
- Melissa Suarez
- Telefonnummer: 718-920-6742
- E-post: mesuarez@montefiore.org
-
Hovedetterforsker:
- Sheldon Feldman, MD
-
Ta kontakt med:
- Linda Castellanos
- Telefonnummer: 718-920-6742
- E-post: lcastellan@montefiore.org
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27710
- Rekruttering
- Duke Cancer Institute
-
Ta kontakt med:
- Breast Cancer Study Team
- Telefonnummer: 919-660-1278
- E-post: breastcl@dm.duke.edu
-
Hovedetterforsker:
- Ton Wang, MD
-
Winston-Salem, North Carolina, Forente stater, 27157
- Rekruttering
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center
-
Hovedetterforsker:
- Marissa Howard-McNatt, MD
-
Ta kontakt med:
- Brandy Baker and Lindsy Davis, RN
- Telefonnummer: 336-716-8941 OR 336-716-6748
- E-post: brandy.baker@advocatehealth.org, lindsey.davis@advocatehealth.org
-
Ta kontakt med:
- Sydney McEntire
- E-post: sydney.mcentire@advocatehealth.org
-
-
Pennsylvania
-
Bryn Mawr, Pennsylvania, Forente stater, 19010
- Aktiv, ikke rekrutterende
- Bryn Mawr Hospital
-
Paoli, Pennsylvania, Forente stater, 19301
- Aktiv, ikke rekrutterende
- Paoli Hospital
-
Wynnewood, Pennsylvania, Forente stater, 19096
- Aktiv, ikke rekrutterende
- Lankenau Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37232
- Rekruttering
- Vanderbilt University Medical Center
-
Hovedetterforsker:
- Ingrid Meszoely, MD
-
Ta kontakt med:
- Oncology nursing
- Telefonnummer: 1-800-811-8480
- E-post: cip@vumc.org
-
Ta kontakt med:
- Jennifer Goodman, RN, BSN
- Telefonnummer: 615.936.6825
- E-post: jennifer.e.goodman@vumc.org
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84112
- Rekruttering
- Huntsman Cancer Institute
-
Hovedetterforsker:
- Kirstyn Brownson, MD
-
Ta kontakt med:
- Janna Espinosa
- Telefonnummer: 801-585-0571
- E-post: Janna.Espinosa@hci.utah.edu
-
-
Virginia
-
Richmond, Virginia, Forente stater, 23298
- Rekruttering
- Virginia Commonwealth University
-
Ta kontakt med:
- Massey CTO Breast Team
- Telefonnummer: 804-628-6430
- E-post: masseyctbrst@vcu.edu
-
Hovedetterforsker:
- Kandace McGuire, MD
-
-
Washington
-
Seattle, Washington, Forente stater, 98109
- Rekruttering
- Univesity of Washington (UW) / Fred Hutchinson Cancer Center (FHCC)
-
Hovedetterforsker:
- Sara Javid, MD
-
Ta kontakt med:
- Sandra Mata-Diaz
- Telefonnummer: 206-221-3762
- E-post: sandramd@uw.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
A. Female, at least 18 years old
B. Previous diagnosis of HR+ DCIS (at least 50% ER or PR; biopsy will have been performed previously at diagnosis) with or without microinvasion
- Patients with a diagnosis of hormone positive DCIS who have undergone surgery with positive margins that have not been re-excised are candidates to enroll in the trial.
C. Patients who have previously received endocrine therapy should have a washout period of at minimum 4-6 weeks prior to the screening MRI on the RECAST-DCIS trial
D. Bilateral mammogram performed within up to 6 months (180 days) of the start of trial treatment may be used for screening evaluation. If a bilateral mammogram has been performed within 1 year (12 months) of the start of trial treatment, then a diagnostic unilateral mammogram within 6 months (180 days) of the start of trial treatment will be acceptable for screening evaluation.
E. MRI performed on an I SPY (RECAST) approved scanner within 2 months (60 days) of the start of trial treatment for lesion evaluation may be used for screening evaluation.
F. CBC w/ diff, CMP, and Lipid Panel within normal limits within a year of the start of trial treatment. Abnormal labs to be repeated within 60 days prior to the start of trial treatment. Patients will be considered eligible for screening labs that are abnormal or out-of-range if the investigator has deemed the lab results not-clinically significant
G. Negative urine or serum pregnancy test within 1 month of the start of trial treatment
H. Controlled HIV positive patients are allowed as long as their current medication does not contraindicate the study's investigational agent
I. Willingness and ability to provide tumor samples for research
Exclusion Criteria:
A. Pregnant or actively breastfeeding women
B. History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history
C. Invasive carcinoma or identification of a mass on MRI that is subsequently biopsied and found to be invasive cancer
D. Co-enrollment in clinical trials of pharmacologic agents requiring an IND
E. Ongoing treatment for DCIS other than what is specified in this protocol
F. Uncontrolled intercurrent illness, including psychiatric conditions, that would limit compliance with study requirements
G. Medical history or ongoing gastrointestinal disorders potentially affecting the absorption of investigational agent and/or tamoxifen. Active inflammatory bowel disease or chronic diarrhea, known active hepatitis A/B/C*, hepatic cirrhosis, short bowel syndrome, or any upper gastrointestinal surgery including gastric resection or banding procedures
*Active hepatitis, defined as: A (positive HA antigen or positive IgM); B (either positive HBs antigen or positive hepatitis B viral DNA test above the lower limit of detection of the assay); C (positive hepatitis C antibody result, and quantitative hepatitis C (HCV) ribonucleic acid (RNA) results greater than the lower limits of detection of the assay)
H. Participants who are unable to swallow normally or unable to take tablets and capsules. Predictable poor compliance with oral treatment
I. Participants with substantial MRI artifacts (e.g., related to localizer sequences, cardiac devices such as pacemakers, or other hardware) that render the lesion non-evaluable.
J. Severe allergy or reaction history to MRI contrast.
K. Participants currently undergoing or who have received treatment for another malignancy within the previous 6 months.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: chemoprevention therapy per investigator choice
For premenopausal women: 20 mg tamoxifen orally daily (standard dose) or 10 mg every other day (low dose). For postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, letrozole 2.5 mg daily, or anastrozole 1 mg daily; or reduced exemestane dosing: 25 mg 3X per week orally. For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (10 mg every other day) or standard dose (20 mg) of tamoxifen. There is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants may continue treatment for up to 5 years. |
For premenopausal women: 20 mg tamoxifen orally daily (standard dose) or 10 mg every other day (low dose). For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (10 mg every other day) or standard dose (20 mg) of tamoxifen. For postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, or reduced exemestane dosing: 25 mg 3 times per week orally For postmenopausal women: standard oral doses of AI of choice: letrozole 2.5 mg daily. For postmenopausal women: standard oral doses of AI of choice: anastrozole 1 mg daily. |
|
Eksperimentell: Testosterone + Anastrazole (T+Ai)
White solid pellet for subcutaneous insertion consisting of 100mg Testosterone and 4mg Anastrazole, an aromatase inhibitor. A cylindrical pellet (4.5mm diameter, 6.35mm diameter) is inserted subcutaneously in the upper outer gluteal region or iliac fossa every 3 months, with treatment up to 36 months. There is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed for an additional 5 years. |
Investigational drug. Both pre- and post- menopausal subjects. 100mg testosterone in combination with 4mg anastrazole administered subcutaneously every 3 months for up to 3 years.
Andre navn:
|
|
Eksperimentell: Elacestrant
Selective estrogen receptor degrader, Standard dose: 400mg PO with food once daily for treatment up to 36 months. Dose reduction of Elacestrant by up to 2 dose levels permitted depending on toxicity; 400 mg to 300 mg then 300 mg to 200 mg Participants requiring more than 2 dose reductions must discontinue treatment For patients on this arm there is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed by for an additional 5 years. |
Investigational drug. Both pre- and post- menopausal subjects. Elacestrant 400mg PO with food once daily up to 36 months. |
|
Eksperimentell: Endoxifen
(Z)-endoxifen is the most active metabolite of the selective estrogen receptor modulator (SERM), tamoxifen. Standard dose: 10mg PO delayed release capsule of z-endoxifen once daily for treatment up to 36 months. same time with a glass of water either 1 hour before a meal or 2 hours after a meal and should not take with alcohol. For patients on this arm there is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed for an additional 5 years. |
Investigational drug. Both pre- and post- menopausal subjects. (z)-endoxifen 10mg delayed release capsule 1 hour before a meal or 2 hours after a meal once daily for up to 36 months. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Patients remaining on active surveillance at 7 months
Tidsramme: 7 months
|
Fraction of patients remaining on active surveillance at 7 months compared to control |
7 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To determine whether novel endocrine therapy increases the fraction of patients who will be suitable for long-term active surveillance as measured by the fraction of patients deemed to be low-risk for invasive cancer at 6 months compared to control
Tidsramme: 6 months
|
Fraction of patients categorized as low risk by MRI after 6 months of treatment--Measured by cases demonstrating endocrine responsiveness (Determined based on lesion and background or lesion alone or lack of lesion and minimal background) |
6 months
|
|
To determine whether novel endocrine therapy increases the fraction of patients who will be suitable for long-term active surveillance as measured by the fraction of patients deemed to be low-risk for invasive cancer at 3 months compared to control
Tidsramme: 3 months
|
Fraction of patients categorized as low risk by MRI after 3 months of treatment--Measured by cases demonstrating endocrine responsiveness (Determined based on lesion and background or lesion alone or lack of lesion and minimal background) |
3 months
|
|
Associate rate of progression to Invasive Ductal Carcinoma (IDC) with risk categorization after 6 months of treatment at 3 years
Tidsramme: 3 years
|
Correlation of low-risk categorization at 6 months with subsequent rate of Invasive Ductal Cell Carcinoma progression at 3 years |
3 years
|
|
To assess the QoL impact of novel endocrine therapy compared to tamoxifen or Aromatase inhibitor (Ai) at standard or low dose using PROMIS and the FACT-ES and FACT-GP5 composite score compared to control
Tidsramme: 6 months
|
Fraction of patients experiencing Minimum Important Difference in overall QOL measured by PROP-R statistics (PROMIS) and FACT-ES (functional assessment of cancer therapy- endocrine symptoms) and FACT-GP5, a quality of life (QoL) assessment) |
6 months
|
|
For those with an identified lesion on MRI imaging, determine whether neoadjuvant endocrine therapy decreases lesion volume (qualitative, quantitative) and whether that corresponds to the biologic type of Ductal cell carcinoma In Situ (DCIS)
Tidsramme: 6 months
|
Rate of reduction in focal lesions (mass and non-mass enhancement (NME) at 6 months and Rate of reduction in focal lesions using automated Functional Tumor Volume |
6 months
|
|
To determine whether neoadjuvant endocrine therapy decreases automated background parenchymal enhancement (BPE and automated MRI density compared to Ai and Tamoxifen
Tidsramme: 6 months
|
% with contralateral reduction in qualitative and automated BPE and % reduction in contralateral breast density |
6 months
|
|
Determine adherence to active surveillance protocol
Tidsramme: 5 years
|
Time to discontinuation of therapy (Tolerability of therapy) will be measured, and Adherence rates on each regimen, as well as PROP-R, FACT-ES and FACT-GP5 score on each regimen will be measured. These assessments will be combined to evaluate efficacy and toxicity using a novel clinical benefit index. |
5 years
|
|
Change in artificial intelligence predicted risk based on mammography
Tidsramme: 5 years
|
Correlation of BPE change with agent and compare to quantitative imaging density |
5 years
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Assess Germ Line polygenic risk: assess correlation of detectable mutations with endocrine response and qualification for active surveillance at 7 months
Tidsramme: 7 months
|
evaluate influence of polygenic risk on endocrine response and suitability for Active Surveillance |
7 months
|
|
To evaluate outcomes stratified by immune and molecular subtype based upon multiplex immuno histochemistry (IHC) clustering analysis, and RPS expression array profiling
Tidsramme: 7 months
|
Response stratified by multiplex immune staining for Human Epidermal growth factor receptor-2 (HER2) isoforms and Response Predictive Subtypes (RPS) |
7 months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Laura Esserman, MD, MBA, University of California, San Fancisco - Department of Surgery
- Hovedetterforsker: (Co-PI) Kelly Hewitt, MD, FACS, Huntsman Cancer Institute at the University of Utah
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Brystkarsinom in situ
- Neoplasmer
- Neoplasmer etter histologisk type
- Neoplasmer, kjertel og epitel
- Adenokarsinom
- Karsinom
- Neoplasmer, duktale, lobulære og medullære
- Karsinom in situ
- Karsinom, intraduktalt, ikke-infiltrerende
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Azoler
- Hydrokarboner
- Hydrokarboner, syklisk
- Hydrokarboner, aromatisk
- Polysykliske forbindelser
- Steroider
- Smeltede ringforbindelser
- Benzenderivater
- Nitriles
- Gonadal steroidhormoner
- Gonadalhormoner
- Androstenes
- Androstanes
- Triazoler
- Stilbenes
- Benzylidenforbindelser
- Androstenols
- Testosteron -kongener
- Letrozol
- Anastrozol
- Testosteron
- Tamoxifen
- eksemestan
- Elacestrant
- 4-hydroksy-n-desmetyltamoxifen
Andre studie-ID-numre
- RECAST-DCIS
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .